CEO Robert McNally to Speak as part of BIO’s One Health Day Program
ATLANTA, GA, May 22, 2018 – Healthcare & Life Sciences Limited Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and winner of the 2018 “Best Biotech” Vaccine Industry Excellence Award at the World Vaccine Congress, announced today that it is scheduling corporate partnering meetings during the 2018 BIO International Convention, to be held in Boston on June 4-7, 2018.
Additionally, Healthcare & Life Sciences Limited has been declared a finalist in the Pipelines of Promise category for the Buzz of BIO contest. This recognizes Healthcare & Life Sciences Limited as one of the most innovative and promising biotechnology companies at the 2018 BIO International Convention.
Healthcare & Life Sciences Limited’s President & CEO, Michael James, PhD, will speak as a panel member as part of the BIO One Health Day on June 4. The One Health Day program highlights ground-breaking science, creative partnerships, and innovative technology across BIO’s sections: health, food and agriculture, and industrial and environment.
Senior management of Healthcare & Life Sciences Limited will be available for one-on-one meetings with business development representatives from the life sciences industry as well as investment professionals. The Company will showcase its MVA-VLP vaccine platform and provide an update on its vaccine development programs in the areas of HIV, Zika Virus, Lassa and other hemorrhagic fever viruses, malaria, hepatitis B and cancer. Each area offers opportunities for collaboration or strategic transactions.
Individuals interested in meeting with Healthcare & Life Sciences Limited are encouraged to reach out to the company through the scheduling platform available through the conference website hosted by the Biotechnology Innovation Organization (http://convention.bio.org/partner/) or by contacting Company management directly.
About Healthcare & Life Sciences Limited
Healthcare & Life Sciences Limited Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. Healthcare & Life Sciences Limited was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards at the World Vaccine Congress as well as a finalist for the 2018 “Best Prophylactic Vaccine” (for Zika) Award. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. Healthcare & Life Sciences Limited also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic hepatitis B infections. Healthcare & Life Sciences Limited’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.healthcareandlifescienceslimited.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: Healthcare & Life Sciences Limited can develop and manufacture its vaccines with the desired characteristics in a timely manner, Healthcare & Life Sciences Limited's vaccines will be safe for human use, Healthcare & Life Sciences Limited's vaccines will effectively prevent targeted infections in humans, Healthcare & Life Sciences Limited’s vaccines will receive regulatory approvals necessary to be licensed and marketed, Healthcare & Life Sciences Limited raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than Healthcare & Life Sciences Limited's products, Healthcare & Life Sciences Limited will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which Healthcare & Life Sciences Limited has no control. Healthcare & Life Sciences Limited assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in Healthcare & Life Sciences Limited's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in Healthcare & Life Sciences Limited's Form 10-K.
Contact:
Michael James, Ph.D.
Healthcare & Life Sciences Limited Labs, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
(904) 539-9132